Post-COVID Myoclonus-Ataxia Syndrome: Evaluation and Management
Post-COVID myoclonus-ataxia syndrome should be treated with early aggressive immunotherapy, specifically intravenous immunoglobulins (IVIG) or corticosteroids, as this para-infectious immune-mediated condition responds rapidly to immunomodulation and delays in treatment can prolong disability.
Clinical Recognition
This is an emerging, distinct neurological syndrome occurring 10 days to 6 weeks after COVID-19 infection 1, 2, 3, 4. The presentation includes:
- Generalized or multifocal myoclonus (often subcortical/brainstem origin)
- Cerebellar ataxia (truncal predominance)
- Opsoclonus or ocular flutter (present in approximately 40-57% of cases)
- Additional features: dysarthria, nystagmus, cognitive changes (30-45% of cases)
The myoclonus typically has acute onset and is disabling, with synchronized EMG bursts that lack EEG correlation, suggesting subcortical rather than cortical origin 1.
Diagnostic Evaluation
Essential Workup
Based on general long COVID guidelines 5, combined with syndrome-specific features:
Blood tests:
- Full blood count, kidney/liver function, CRP, ferritin
- Thyroid function, B-type natriuretic peptide
- COVID-19 serology (typically strongly positive) 2
- Autoimmune and paraneoplastic antibody panels (usually negative, but MOG antibodies reported in one case) 6
Neurophysiology:
- EMG to characterize myoclonus (synchronized bursts)
- EEG (typically normal or shows no correlation with myoclonus)
- Somatosensory evoked potentials (may be absent, supporting subcortical origin) 1
Imaging:
- Brain MRI (typically normal) 2, 3
- Chest CT if respiratory symptoms present (may show post-COVID infiltrates)
CSF analysis should be considered to rule out active CNS infection and assess for autoantibodies 6.
Treatment Algorithm
First-Line Immunotherapy
The critical decision is choosing between IVIG and corticosteroids:
IVIG is preferred based on the most recent case evidence showing rapid and marked recovery 7. One 2025 case demonstrated minimal response to corticosteroids but dramatic improvement with IVIG, suggesting IVIG may be superior for some patients.
Intravenous methylprednisolone is an effective alternative, with multiple cases showing notable improvement and good outcomes at 2-month follow-up 1, 2.
Combined therapy (IVIG + steroids) has been used successfully in several cases 4.
Timing is critical: Early aggressive immunotherapy (within days to weeks of symptom onset) correlates with better outcomes 1, 4. Most treated patients improve within 1 week to 2 months 3, 4.
Adjunctive Symptomatic Treatment
- Anti-myoclonic medications (e.g., clonazepam, levetiracetam) provide partial symptomatic relief but do not address the underlying pathophysiology 2, 8
- These should be used as adjuncts to immunotherapy, not as monotherapy
Critical Pitfalls
Insurance/access barriers: The 2025 case report highlights how delayed IVIG access due to insurance limitations prolonged disease progression 7. Advocate aggressively for rapid approval given the time-sensitive nature of this condition.
Misdiagnosis as primary movement disorder: The post-infectious timeline (10 days to 6 weeks after COVID-19) is pathognomonic and distinguishes this from other causes 1, 2, 3.
Undertreatment: Spontaneous improvement can occur but is unpredictable. Given the disabling nature and evidence for rapid response to immunotherapy, treatment should not be withheld 3, 4.
Prognosis and Follow-up
Most cases improve within 2 months with appropriate treatment 3, 4. However, untreated or delayed treatment can result in prolonged disability or, rarely, fatal outcomes 8.
Follow-up should include:
- Monitoring for symptom resolution or recurrence
- Functional assessment (activities of daily living, mobility)
- Consideration of multidisciplinary rehabilitation if residual deficits persist 5
The natural history remains incompletely characterized, and some patients may have episodic symptoms requiring ongoing monitoring 9, 3.